RareCyte Prostate Cancer RarePlex Staining Kit

RareCyte has launched a new RarePlex Staining Kit for evaluating prostate cancer specific expression of ARv7 on circulating tumor cells. When combined with the firm's CTC analysis platform, the RarePlex ARv7 CTC Panel kit allows researchers to perform first blood-to-result prostate-specific CTC assay in their laboratories. RareCyte said the kit contains CTC detection markers in addition to ARv7 and can be performed on an automated slide staining system.